Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

bioMerieux targets breast cancer theranostics with Ipsen

This article was originally published in Clinica

Executive Summary

Marcy l'Etoile-based diagnostics company bioMerieux is to collaborate with fellow French pharmaceutical firm Ipsen on diagnostic-and-therapy solution for breast cancer patients. Under the agreement, bioMerieux will develop a test to determine which patients are best suited to benefit from a new breast cancer drug, BN83495, that Paris-based Ipsen is currently investigating. The test, based on bioMerieux's NucliSENS EasyQ molecular diagnostics platform, will be used in the clinical development of the Ipsen drug and for diagnostic purposes, with the potential for future commercialisation. According to WHO figures, breast cancer is the most prevalent form of cancer worldwide with 1.1 million new cases diagnosed each year. The disease is responsible for over 500,000 deaths each year.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT049732

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel